Patents Assigned to Paradigm Diagnostics, Inc.
  • Publication number: 20230407244
    Abstract: Microbial growth media and methods of growing a microorganism. The microbial growth media may include a growth-stimulating amount of phosphoglucomutase in combination with one or more of a carbon and nitrogen source, a fermentable sugar, and an inorganic salt. The methods of growing a microorganism may include culturing a sample suspected of containing the microorganism in a microbial growth medium containing a growth-stimulating amount of phosphoglucomutase. Microbial growth-stimulating protein compositions and uses of same are also provided.
    Type: Application
    Filed: October 26, 2021
    Publication date: December 21, 2023
    Applicant: Paradigm Diagnostics, Inc.
    Inventor: Alan D Olstein
  • Patent number: 11732285
    Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: August 22, 2023
    Assignee: Paradigm Diagnostics, Inc.
    Inventor: Alan D Olstein
  • Publication number: 20200208099
    Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.
    Type: Application
    Filed: March 10, 2020
    Publication date: July 2, 2020
    Applicant: Paradigm Diagnostics, Inc.
    Inventor: Alan D. Olstein
  • Patent number: 10619130
    Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: April 14, 2020
    Assignee: PARADIGM DIAGNOSTICS, INC.
    Inventor: Alan D Olstein
  • Patent number: 9518283
    Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. and/or Shiga toxin-producing E. coli. The media may comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, nitrofurantoin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. Methods of selectively growing and detecting Salmonella and/or Shiga toxin-producing E. coli are provided.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: December 13, 2016
    Assignee: Paradigm Diagnostics, Inc.
    Inventor: Alan D. Olstein
  • Patent number: 9029118
    Abstract: Selective enrichment media and methods for selectively growing and detecting Salmonella spp. The media comprise a carbon and nitrogen source, an inorganic salt, a fermentable sugar, one or more selective agents, and an efflux pump inhibitor. Various selective agents include sulfa drugs, surfactants, aminocoumarins, cycloheximide, supravital stains, ascorbic acid, bromobenzoic acid, myricetin, rifamycins, polyketides, and oxazolidinones. Various efflux pump inhibitors include arylpiperazines, such as 1-(1-naphthylmethyl)piperazine, and quinoline derivatives, such as 4-chloroquinoline. The selective agents and efflux pump inhibitors are provided in the media in combinations and amounts that inhibit growth of non-Salmonella microorganisms without substantially affecting growth and metabolism of Salmonella species. Methods of selectively growing and detecting Salmonella species are provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: May 12, 2015
    Assignee: Paradigm Diagnostics, Inc.
    Inventor: Alan D Olstein
  • Patent number: 7960164
    Abstract: The invention is a selective growth medium for investigating, isolating, counting and directly identifying pathogenic bacteria of the genus Listeria.The medium promotes the Listeria spp. while simultaneously inhibiting the growth of non-Listeria organisms. The medium does not produce a bacterial biomass contaminated with interfering fluorophores. The medium contains nitrofurantoin, esculin and lithium chloride and lacks acriflavin.
    Type: Grant
    Filed: February 12, 2005
    Date of Patent: June 14, 2011
    Assignee: Paradigm Diagnostics, Inc.
    Inventor: Alan D. Olstein